| No information available. |
Summary of Clinical Use  |
| IC14 was in clinical development for sepsis and ALS but none of the trials are active. It was progressed for COVID-19 in 2020. Results from early stage studies in healthy subjects, LPS-challenged subjects and patients with sepsis were reported in 2003 [2]. As of March 2024 most clinical trials involving IC14 had been terminated or withdrawn. The FDA's designation of IC14 as an orphan drug for ALS (issued in January 2021) appeared to still be in place at that time. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT00042588 | A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis | Phase 2 Interventional | ICOS Corporation | ||
| NCT04346277 | Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19) | Expanded Access | Implicit Bioscience | ||
| NCT04391309 | IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19) | Phase 2 Interventional | Implicit Bioscience | ||
| NCT04488081 | I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients | Phase 2 Interventional | QuantumLeap Healthcare Collaborative | ||
| NCT04309604 | IC14 for ALS Patients Expanded Access | Expanded Access | Implicit Bioscience | 3 | |
